Cost of noninfectious comorbidities in patients with HIV

ClinicoEconomics and Outcomes Research

Volumn 5, Issue 1, 2013, Pages 481-488

  Guaraldi, Giovanni ^a   Zona, Stefano ^a   Menozzi, Marianna ^a   Carli, Federica ^a   Bagni, Pietro ^a   Berti, Alessandra ^b   Rossi, Elisa ^b   Orlando, Gabriella ^a   Zoboli, Giuliana ^c   Palella, Frank ^d  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b CINECA   (Italy)

^c Division of Infectious Diseases   (Italy)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; HIV; Noninfectious comorbidities; Pharmacoeconomics

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FRACTURE; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE;

EID: 84884565423     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/CEOR.S40607     Document Type: Article

References (48)

1. Scitovsky AA, Rice D P. Estimates of the direct and indirect costs of acquired immunodefciency syndrome in the United States, 1985, 1986, and 1991. Public Health Rep. 1987;102(1):5-17.
2. Scitovsky AA, Cline M, Lee PR. Medical care costs of patients with AIDS in San Francisco. JAMA. 1986;256(22):3103-3106.
3. Bozzette SA, Joyce G, McCaffrey D F, et al; HIV Cost and Services Utilization Study Consortium. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med. 2001;344(11):817-823.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodefciency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-860.
5. Moore RD, Chaisson RE. Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS. 1999;13(14):1933-1942.
6. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med. 1997;336(21):1531-1532.
7. Gonzalo T, Garcia Goni M, Munoz-Fernandez MA. Socio-economic impact of antiretroviral treatment in HIV patients. An economic review of cost savings after introduction of HAART. AIDS Rev. 2009; 11(2):79-90.
8. Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS. 1999;13(8):963-969.
9. Hill A, Hemmett L, Wilson B. Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trials. HIV Clin Trials. 2007; 8(5):303-310.
10. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4, 200 cells/microL) with HIV infection. HIV Med. 2004;5(2):93-98.
11. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS. 2008;22(18):2409-2418.
12. Weber R, Sabin CA, Friis-Møller N, et al. Liver-related deaths in persons infected with the human immunodefciency virus: the D:A:D study. Arch Intern Med. 2006;166(15):1632-1641.
13. Justice AC. Prioritizing primary care in HIV: comorbidity, toxicity, and demography. Top HIV Med. 2006;14(5):159-163.
14. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med. 2006;145(6):397-406.
15. Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ. 2009;338:a3172.
16. Shah SS, McGowan J P, Smith C, Blum S, Klein RS. Comorbid conditions, treatment, and health maintenance in older persons with human immunodefciency virus infection in New York City. Clin Infect Dis. 2002;35(10):1238-1243.
17. Vance DE, Mugavero M, Willig J, Raper JL, Saag MS. Aging with HIV: a cross-sectional study of comorbidity prevalence and clinical characteristics across decades of life. J Assoc Nurses AIDS Care. 2011; 22(1):17-25.
18. Justice AC. HIV and aging: time for a new paradigm. Current HIV/ AIDS Rep. 2010;7(2):69-76.
19. Fried L P, Tangen CM, Walston J, et al; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146-M156.
20. Goulet JL, Fultz SL, Rimland D, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis. 2007;45(12):1593-1601.
21. Gebo KA, Fleishman JA, Conviser R, et al; HIV Research Network. Contemporary costs of HIV healthcare in the HAART era. AIDS. 2010; 24(17):2705-2715.
22. Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. J Antimicrob Chemother. 2006;57(1):4-7.
23. Guaraldi G, Zona S, Alexopoulos N, et al. Coronary aging in HIV-infected patients. Clin Infect Dis. 2009;49(11):1756-1762.
24. ARNO Osservatorio [database on the Internet]. CINECA. Available from: http://osservatorioarno.cineca.org. Accessed January 17, 2012. Italian.
25. International Classification of Diseases (ICD): 9th revision, basic tabulation list with alphabetic index. Geneva: World Health Organization; 1978. Available from: http://www.cdc.gov/nchs/icd/icd9.htm. Accessed May 31, 2013.
26. Krentz HB, Gill MJ. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006. HIV Med. 2008; 9(9):721-730.
27. Agenzia Italiana del Farmaco (AIFA) [homepage on the Internet]. Available from: http://www.agenziafarmaco.gov.it/. Accessed January 17, 2012.
28. Topinková E. Aging, disability and frailty. Ann Nutr Metab. 2008; 52(1):6-11.
29. Revised classification system for HIV infection and expanded surveillance case defnition for AIDS among adolescents and adults [webpage on the Internet]. Atlanta, GA: Centers for Disease Control and Prevention (CDC); 1993. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. Accessed May 31, 2013.
30. Walensky R P, Paltiel AD, Losina E, et al. The survival benefts of AIDS treatment in the United States. J Infect Dis. 2006;194(1):11-19.
31. Berthelot JM, Will B P, Evans WK, Coyle D, Earle CC, Bordeleau L. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. J Natl Cancer Inst. 2000; 92(16):1321-1329.
32. Norum J. Adjuvant cyclophosphamide, methotrexate, fuorouracil (CMF) in breast cancer - is it cost-effective? Acta Oncol. 2000;39(1):33-39.
33. Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med. 1998;339(13):861-867.
34. Kuntz KM, Tsevat J, Goldman L, Weinstein MC. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation. 1996;94(5):957-965.
35. Weintraub WS, Mahoney EM, Lamy A; CURE Study Investigators. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. J Am Coll Cardiol. 2005;45(6):838-845.
36. Beck EJ, Mandalia S, Youle M, et al. Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002). Int J STD AIDS. 2008;19(5):297-304.
37. de Meijer C, Koopmanschap M, D'Uva TB, van Doorslaer E. Determinants of long-term care spending: age, time to death or disability? J Health Econ. 2011;30(2):425-438.
38. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, Garlassi E, et al. Premature Age-Related Comorbidities Among HIV-Infected Persons Compared With the General Population. Clin Infect Dis. 2011;53(11)1120-1126.
39. Levy AR, James D, Johnston KM, et al. The direct costs of HIV/AIDS care. Lancet Infect Dis. 2006;6(3):171-177.
40. Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis. 2006; 42(7):1003-1010.
41. Deeks SG. Immune dysfunction, infammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med. 2009;17(4):118-123.
42. Kirk JB, Goetz MB. Human immunodefciency virus in an aging population, a complication of success. J Am Geriatr Soc. 2009; 57(11):2129-2138.
43. Effros RB, Fletcher C V, Gebo K, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis. 2008;47(4):542-553.
44. Magoni M, Scarcella C, Vassallo F, et al. The evolving burden of HIV infection compared with other chronic diseases in northern Italy. HIV Med. 2011;12(3):129-137.
45. Strategies for Management of Antiretroviral Therapy (SMART) Study Group; El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006; 355(22):2283-2296.
46. When To Start Consortium; Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352-1363.
47. Luther V P, Wilkin AM. HIV infection in older adults. Clin Geriatr Med. 2007;23(3):567-583, vii.
48. Mandalia S, Mandalia R, Lo G, et al; NPMS-HHC Steering Group. Rising population cost for treating people living with HIV in the UK, 1997-2013. PLoS One. 2010;5(12):e15677.